Sage Therapeutics (SAGE, Financial) experienced significant stock price fluctuations recently. Initially, the stock fell over 13% but later recovered, trading at a 0.5% gain to $6.756.
The volatility followed the company's announcement that it would cease the development of its Alzheimer's drug. This decision came after the drug failed to meet primary goals in a mid-stage trial.
